Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 118, Issue 12, Pages 1609-1616
Publisher
Springer Nature
Online
2018-06-05
DOI
10.1038/s41416-018-0115-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial
- (2017) Takayuki Yoshino et al. EUROPEAN JOURNAL OF CANCER
- Prognostic value of circulating endothelial cells in metastatic colorectal cancer
- (2017) Nuh N. Rahbari et al. Oncotarget
- A high preoperative carbohydrate antigen 19-9 level is a risk factor for recurrence in stage II colorectal cancer
- (2016) Hiroaki Nozawa et al. ACTA ONCOLOGICA
- Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study
- (2016) Tal Grenader et al. BRITISH JOURNAL OF CANCER
- From tumour heterogeneity to advances in precision treatment of colorectal cancer
- (2016) Cornelis J. A. Punt et al. Nature Reviews Clinical Oncology
- Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
- (2016) Maria Thomsen et al. Oncotarget
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
- (2015) Halfdan Sorbye et al. PLoS One
- Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
- (2014) Gerald W. Prager et al. CANCER SCIENCE
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy
- (2014) M. Tampellini et al. TUMOR BIOLOGY
- Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis
- (2013) Nicole Beauchemin et al. CANCER AND METASTASIS REVIEWS
- Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update
- (2013) M.J. Duffy et al. INTERNATIONAL JOURNAL OF CANCER
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
- (2012) Kjell Magne Tveit et al. JOURNAL OF CLINICAL ONCOLOGY
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
- (2012) Douglas G. Altman et al. PLOS MEDICINE
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- C-stage in Colon Cancer: Implications of Carcinoembryonic Antigen Biomarker in Staging, Prognosis, and Management
- (2011) Pragatheeshwar Thirunavukarasu et al. JNCI-Journal of the National Cancer Institute
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy
- (2009) A. S. Strimpakos et al. ANNALS OF ONCOLOGY
- Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report
- (2009) M. J. Duffy et al. ANNALS OF ONCOLOGY
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now